The arms race over the next generation of obesity drugs is continuing to heat up. This week, pharmaceutical company Eli Lilly announced it was suing several pharmacies, spas, and wellness centers in the U.S. for allegedly selling unauthorized copycats of its blockbuster drug tirzepatide, which is expected to be…
